Aadi Biosciences (AADI) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

AADI Aadi Biosciences

Watchlist

2.300
+0.020+0.88%

Close Nov 22 16:00 ET

2.300
0.0000.00%

Post 20:01 ET

56.69MMarket Cap-1008P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Aadi Bioscience Inc : Jefferies Raises Target Price to $2 From $1.5
ReutersNov 7 01:10 ET
Aadi Biosciences | 10-Q: Q3 2024 Earnings Report
SECNov 6 16:14 ET · Announcements
Aadi Biosciences | 8-K: Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update
SECNov 6 08:07 ET
Express News | Aadi Bioscience Remains Actively Engaged In A Comprehensive Strategic Review To Maximize Shareholder Value
BenzingaNov 6 08:05 ET
Express News | Aadi Bioscience Is Completing Wind-down Of PRECISION1 Trial Of Nab-sirolimus In Patients With Solid Tumors Harboring TSC1 Or TSC2 Inactivating Alterations
BenzingaNov 6 08:04 ET
Aadi Bioscience GAAP EPS of -$0.46 In-line, Revenue of $7.21M Beats by $0.61M
Seeking AlphaNov 6 08:03 ET

Comments

Jaguar8

Aug 20 16:01

NEWS

$Aadi Biosciences (AADI.US)$
Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates
Aadi Bioscience (NASDAQ: AADI) has announced the halt of its PRECISION1 trial for nab-sirolimus in solid tumors with TSC1 or TSC2 alterations due to unlikely regulatory approval. The company will now focus on its FYARRO® commercial business for PEComa and conduct a strategic review. To extend cash runway into at least 2H 2026, Aadi will:
Adjust ongoing Phase 2 trials
Reduce R&D headcount by 80%
Pause...

Jaguar8

May 23 16:34

$Aadi Biosciences (AADI.US)$
NEWS
Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting
Aadi Bioscience presented new nonclinical data at the ASCO Annual Meeting showing that nab-sirolimus achieved higher intratumoral drug concentrations, stronger mTOR target inhibition, and greater antitumor activity compared to IV and oral mTOR inhibitors in a xenograft model. These findings suppo...

Moomoo AI

Mar 8 06:17

Aadi Bioscience's low P/S ratio may be due to its poor revenue outlook. Investors may believe the potential for revenue improvement doesn't justify a higher P/S ratio. These conditions could continue to limit the share price.